ESR1 and neoplasm: In the present study, a strict criteria of ASCO/CAP guideline recommendations for IHC-based testing of ER and PR was adopted (ER or PR are considered negative if <1% of tumor cell nuclei are immunoreactive) to identify the TNBC phenotype (16), which significantly diminished the number of TNBC cases included in the study.